US EditionAdcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
8 Articles
8 Articles
The French biotech Adcytherix has just raised €105 million to start clinical trials of its products.
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (a Citadel company) and aMoon, and with renewed participation from all existing shareholders, including Pontifax, DawnBiopharma (a platform controlled by K…
Founded in 2024 in Marseille, Adcytherix has completed a funding of 105 million euros, an exceptional amount for a series A in human health. The operation places the company among the leaders in the field of antibodies medicines, a therapeutic approach that is growing in oncology.
ADC specialist Adcytherix SAS raises €105m in Series A round - European Biotechnology Magazine
French ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance. The post ADC specialist Adcytherix SAS raises €105m in Series A round appeared first on European Biotechnology Magazine.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
